EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis

Salman Bhai iD, Todd Levine, Dan Moore, Robert Bowser, Andrew J Heim iD, Maureen Walsh, Aziz Shibani, Zachary Simmons iD, James Grogan, Namita A Goyal, Raghav Govindarajan, Yessar Hussain und 15 weitere

Muscle & Nerve · 2025-01 · 71 (1) · 63-72

DOI: 10.1002/mus.28287 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, online erschienen am 07.11.2024. Verfasst von Salman Bhai und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Memantine, Amyotrophic Lateral Sclerosis, Disease Progression. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, FDA-OPD, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no known cure, limited treatment options with minimal benefits, and significant unmet need for disease modifying therapies.

Aims

This study investigated memantine's impact on ALS progression, with an additional focus on the effects of memantine on cognitive and behavioral changes associated with the disease.

Methods

A randomized, double‐blind, placebo‐controlled clinical trial was conducted from December 2018 to September 2020. ALS patients were enrolled in‐person and remotely across 13 sites in the United States. Participants were randomized to memantine (20 mg twice daily) or placebo in a 2:1 ratio and completed 36 weeks of treatment. The primary outcome of disease progression was assessed by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R), and blood was collected for biomarker analysis.

Results

Of the 99 participants enrolled in the study, 89 were randomized to memantine or placebo (ages 24–83 years, male‐to‐female ratio ~3:2). Fifty‐two participants completed the study treatment with no significant differences in disease progression, biomarker changes (including neurofilament light chain [NfL]), or neuropsychiatric testing noted between the groups. Initial NfL values correlated with the rate of ALSFRS‐R decline.

Discussion

In this study, memantine did not impact ALS disease progression or neuropsychiatric symptoms. Trials with remote enrollment may help trial participation and success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineAmyotrophic Lateral SclerosisDisease ProgressionHumansMaleFemaleDouble-Blind MethodMiddle AgedAgedAdultAged, 80 and overTreatment OutcomeYoung AdultExcitatory Amino Acid Antagonists

Stichwörter der Autor:innen

amyotrophic lateral sclerosis (ALS)biomarkersmemantinemotor neuron disease (MND)neurofilament

Substanzen

MemantineExcitatory Amino Acid Antagonists

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Neuromuscular Center, Institute for Exercise and Environmental Medicine, Texas Health Dallas, Dallas, Texas, USA.
  • Honor Health, Scottsdale, Arizona, USA.
  • Calico Consulting, Livermore, California, USA.
  • Barrow Neurological Institute, Phoenix, Arizona, USA.
  • University of Kansas Medical Center, Kansas City, Kansas, USA.

ORCID-Profile: Salman Bhai, Andrew J Heim, Zachary Simmons, Tiffany Schwasinger-Schmidt, Michael Weiss, Jeffrey Statland

Förderung

  • FDA HHS
  • FDA-OPD
  • U.S. Food and Drug Administration

Zitieren

APA

Bhai, S., Levine, T., Moore, D., Bowser, R., Heim, A. J., Walsh, M., Shibani, A., Simmons, Z., Grogan, J., Goyal, N. A., Govindarajan, R., Hussain, Y., Papsdorf, T., Schwasinger-Schmidt, T., Olney, N., Goslin, K., Pulley, M., Kasarskis, E., Weiss, M., …, & Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group (2025). A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis. Muscle & Nerve, 71(1), 63-72. https://doi.org/10.1002/mus.28287

Vancouver

Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, et al. A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis. Muscle & Nerve. 2025;71(1):63-72. doi:10.1002/mus.28287

BibTeX
@article{Bhai2025,
  author = {Bhai, Salman and Levine, Todd and Moore, Dan and Bowser, Robert and Heim, Andrew J and Walsh, Maureen and Shibani, Aziz and Simmons, Zachary and Grogan, James and Goyal, Namita A and Govindarajan, Raghav and Hussain, Yessar and Papsdorf, Tania and Schwasinger-Schmidt, Tiffany and Olney, Nick and Goslin, Kim and Pulley, Michael and Kasarskis, Edward and Weiss, Michael and Katz, Susan W and Moser, Suzan and Jabari, Duaa and Jawdat, Omar and Statland, Jeffrey and Dimachkie, Mazen M and Barohn, Richard and Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group, Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group},
  title = {A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis},
  journal = {Muscle & Nerve},
  year = {2025},
  volume = {71},
  number = {1},
  pages = {63--72},
  doi = {10.1002/mus.28287}
}
Kostenlos starten →